References
- Ablynx. News release: Ablynx announces positive topline results from a phase 2b study of its anti-IL-6r nanobody, vobarilizumab (alx-0061), as a monotherapy in RA. 2016 Jul 7.
- Staff. NICE approves UCB Pharma’s Cimzia. PMLiVE. 2016 Jul 12.
Related Articles
Rheumatology Drug Updates: Ixekizumab Improves Work Productivity, plus Vobarilizumab Completes Phase 2 Trial in Rheumatoid Arthritis
Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis Indirect costs of reduced work productivity can have a significant impact on a patient’s quality of life. A recent article published in JAMA Dermatology analyzed the results of three multicenter, randomized double-blind Phase 3 trials, UNCOVER-1, UNCOVER-2 and UNCOVER-3, which evaluated the effect of ixekizumab on…
Certolizumab Pegol Usage Compatible with Breastfeeding
In a small-scale study, researchers found that no, or minimal amounts of, certolizumab pegol transfers from mothers taking the drug to nursing infants…
EU Approves Certolizumab Pegol for Pregnant & Nursing Patients
In the EU, certolizumab pegol has been approved for use in pregnant and nursing women with chronic rheumatic disease…
Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…